Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial

Jozine M Ter Maaten, Iris E Beldhuis, Peter van der Meer, Jan A Krikken, Jenifer E Coster, Wybe Nieuwland, Dirk J van Veldhuisen, Adriaan A Voors, Kevin Damman, Jozine M Ter Maaten, Iris E Beldhuis, Peter van der Meer, Jan A Krikken, Jenifer E Coster, Wybe Nieuwland, Dirk J van Veldhuisen, Adriaan A Voors, Kevin Damman

Abstract

Aims: Insufficient diuretic response frequently occurs in patients admitted for acute heart failure (HF) and is associated with worse clinical outcomes. Recent studies have shown that measuring natriuresis early after hospital admission could reliably identify patients with a poor diuretic response during hospitalization who might require enhanced diuretic treatment. This study will test the hypothesis that natriuresis-guided therapy in patients with acute HF improves natriuresis and clinical outcomes.

Methods: The Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) is a pragmatic, single-centre, randomized, controlled, open-label study, aiming to recruit 310 acute HF patients requiring treatment with intravenous loop diuretics. Patients will be randomized to natriuresis-guided therapy or standard of care. Natriuresis will be determined at set time points after initiation of intravenous loop diuretics, and treatment will be adjusted based on the urinary sodium levels in the natriuresis-guided group using a pre-specified stepwise approach of increasing doses of loop diuretics and the initiation of combination diuretic therapy. The co-primary endpoint is 24-h urinary sodium excretion after start of loop diuretic therapy and a combined endpoint of all-cause mortality or first HF rehospitalization at 6 months. Secondary endpoints include 48- and 72-h sodium excretion, length of hospital stay, and percentage change in N-terminal pro brain natriuretic peptide at 48 and 72 h.

Conclusion: The PUSH-AHF study will investigate whether natriuresis-guided therapy, using a pre-specified stepwise diuretic treatment approach, improves natriuresis and clinical outcomes in patients with acute HF.

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Figures

Figure 1
Figure 1
In patients with acute heart failure, loop diuretics are the first and only recommended choice of treatment aimed at relieving congestion by increasing diuresis and natriuresis. Actively assessing natriuresis and using this to optimize diuretic treatment could improve decongestion and clinical outcomes. This figure was created with images adapted from Servier Medical Art licensed under a Creative Commons Attribution 3.0.
Figure 2
Figure 2
Overview of the PUSH‐AHF study protocol. HF, heart failure; iv, intravenous; LD, loop diuretic; NT‐proBNP, N‐terminal pro brain natriuretic peptide.
Figure 3
Figure 3
(A) PUSH‐AHF treatment protocol in the natriuresis‐guided arm during the first 24 h (0–24 h after randomization). (B) PUSH‐AHF treatment protocol in the natriuresis‐guided arm during the second 24 h (24–48 h after randomization). eGFR, estimated glomerular filtration rate; HCT, hydrochlorothiazide; LD, loop diuretic; SGLT2‐i, sodium–glucose co‐transporter inhibitor.
Figure 4
Figure 4
PRECIS‐2 wheel diagram for the PUSH‐AHF study.PRECIS‐2, Pragmatic Explanatory Continuum Indicator Summary 2; PUSH‐AHF, Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure.

References

    1. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93:1137–46.
    1. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391–403.
    1. Valente MA, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O'Connor CM, et al. Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J. 2014;35:1284–93.
    1. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail. 2014;7:261–70.
    1. ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors AA. Diuretic response in acute heart failure‐pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12:184–92.
    1. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long‐term outcomes in acute decompensated heart failure. J Card Fail. 2014;20:392–9.
    1. Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. Acta Cardiol. 2015;70:265–73.
    1. Biegus J, Zymliński R, Sokolski M, Todd J, Cotter G, Metra M, et al. Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. Eur J Heart Fail. 2019;21:624–33.
    1. Hodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J, et al. Natriuretic response is highly variable and associated with 6‐month survival: insights from the ROSE‐AHF trial. JACC Heart Fail. 2019;7:383–91.
    1. Damman K, Ter Maaten JM, Coster JE, Krikken JA, van Deursen VM, Krijnen HK, et al. Clinical importance of urinary sodium excretion in acute heart failure. Eur J Heart Fail. 2020;22:1438–47.
    1. Testani JM, Hanberg JS, Cheng S, Rao V, Onyebeke C, Laur O, et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ Heart Fail. 2016;9:e002370.
    1. Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner‐La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:137–55.
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members, Document Reviewers . ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
    1. Boorsma EM, Ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol. 2020;17:641–55.
    1. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–9.
    1. Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm Drug Dispos. 2001;22:147–56.
    1. Ter Maaten JM, Rao VS, Hanberg JS, Perry Wilson F, Bellumkonda L, Assefa M, et al. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur J Heart Fail. 2017;19:1014–22.
    1. Rao VS, Planavsky N, Hanberg JS, Ahmad T, Brisco‐Bacik MA, Wilson FP, et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol. 2017;28:3414–24.
    1. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–43.
    1. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al.; NHLBI Heart Failure Clinical Research Network . Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
    1. Ter Maaten JM, Damman K. Down the road from challenges in acute heart failure trials. Eur J Heart Fail. 2019;21:1423–5.
    1. Rao VS, Ivey‐Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, et al. Natriuretic equation to predict loop diuretic response in patients with heart failure. J Am Coll Cardiol. 2021;77:695–708.
    1. Matsue Y, Damman K, Voors AA, Kagiyama N, Yamaguchi T, Kuroda S, et al. Time‐to‐furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017;69:3042–51.
    1. ter Maaten JM, Dunning AM, Valente MA, Damman K, Ezekowitz JA, Califf RM, et al. Diuretic response in acute heart failure‐an analysis from ASCEND‐HF. Am Heart J. 2015;170:313–21.
    1. Grodin JL, Stevens SR, de Las Fuentes L, Kiernan M, Birati EY, Gupta D, et al. Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure. J Card Fail. 2016;22:26–32.
    1. Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, et al. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. BMJ. 2021;372:m4786.
    1. Ahmad T, Yamamoto Y, Biswas A, Ghazi L, Martin M, Simonov M, et al. REVeAL‐HF: design and rationale of a pragmatic randomized controlled trial embedded within routine clinical practice. JACC Heart Fail. 2021;9:409–19.
    1. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS‐2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.
    1. Greene SJ, Velazquez EJ, Anstrom KJ, Eisenstein EL, Sapp S, Morgan S, et al.; TRANSFORM‐HF Investigators . Pragmatic design of randomized clinical trials for heart failure: rationale and design of the TRANSFORM‐HF trial. JACC Heart Fail. 2021;9:325–35.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться